Cite
HARVARD Citation
Lassman, A. et al. (n.d.). OS10.6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study. Neuro-oncology. pp. iii21-iii22. [Online].